The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Tue., Apr. 20, 2:23 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #21. Emergent BioSolutions Cangene Corporation

Acquirer: Emergent BioSolutions (NYSE:EBS)
Acquiree: Cangene Corporation (CNJ)
Details: Cangene Corporation ("Cangene") (TSX: CNJ) announced that its shareholders have approved the previously announced acquisition by Emergent BioSolutions ("Emergent") (NYSE: EBS) at a special meeting held today. The acquisition will be implemented through a Plan of Arrangement under Canadian law, under which Cangene shareholders will receive US$3.24 per share (C$3.571 per share) in cash, for an aggregate purchase price of US$222 million (approximately C$245 million2).

Emergent BioSolutions is a life sciences company focused on providing a portfolio of preparedness and response products and solutions that address accidental, deliberate and naturally occurring public health threats (PHTs). Co. is focused on products and solutions that address the following five distinct PHT categories: Chemical, Biological, Radiological, Nuclear and Explosives; emerging infectious diseases; travel health; emerging health crises; acute/emergency care; and contract development and manufacturing (CDMO). Co. has a product portfolio of ten marketed products (vaccines, therapeutics, and drug-device combination products).

EBS SEC Filing Email Alerts Service

Open the EBS Page at The Online Investor »

Company Name: 
Emergent BioSolutions Inc
Stock buyback: 
EBS buyback
Number of ETFs Holding EBS: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the EBS Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Buy (3.14 out of 4)
36th percentile
(ranked lower than approx. 64% of all stocks covered)

Analysts' Target Price:
EBS Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 21 of 83 Page |

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.